Abstract: A pill pouch is disclosed. The pill pouch can include a receptacle to contain a pill. The receptacle can have an opening to receive the pill therein. The receptacle can be defined at least in part by a flexible side to facilitate breaking or crushing of the pill inside the receptacle. The pill pouch can also include an access feature associated with the receptacle to facilitate removal of the pill from the receptacle after the pill has been broken and/or crushed.

Abstract: The present invention is a medication dispensing system and device comprising a multiple compartment dispensing cartridge made of rigid and flexible materials. The cartridge is preloaded with dispensable contents and inserted into the housing of the dispensing device. A flexible ribbon with an opening run through a plurality of slits in the vertical walls in a closed loop manner resulting in formation of compartments. The ribbon is moved, by a motor, such that the opening reaches a specific compartment at a specific time, thereby releasing the contents of that compartment at that time. Other features, such as a microcontroller is provided to control the dispensing date and time of the contents based on pre-determined conditions.

Abstract: A pacifier for dispensing a liquid such as milk, the pacifier including a nipple, including a milk entering aperture disposed at a first end of the nipple, a milk expelling aperture disposed at a second end of the nipple opposite from the first end of the nipple, and a milk holding portion to hold milk therein and to receive the nipple, the milk receiving portion including a milk supplying aperture to correspond to the milk entering aperture of the nipple to supply milk from the milk holding portion to the nipple.

Abstract: Disclosed is a personal care composition comprising: a) a porous particle; b) a film forming polymer; and c) a cosmetically acceptable carrier which is a water and oil emulsion; wherein the porous particle has oil absorption value in the range of 50 g/100 g to 1500 g/100 g; wherein the porous particle is selected from porous silica, cellulose, acrylic polymer, nylon and ethylene/methacylate copolymer hollow sphere coated with porous silica; wherein the film forming polymer is selected from an acrylate polymer, a methacrylate polymer, a urethane polymer or co-polymers thereof; and wherein the composition comprises whitening pigment in an amount of from 0.001 to 2 wt %.

Abstract: A water-in-oil emulsion cosmetic, has good stability and does not cause a decrease in viscosity when a large quantity of fragrance material is blended. The water-in-oil emulsion cosmetic, includes: (a) 5 to 15% by mass of a fragrance material, (b) 1.5 to 3% by mass of dimethyldistearylammonium hectorite, and, (c) a nonionic surfactant, wherein, the (c) nonionic surfactant comprises (c1) 2 to 10% by mass relative to the total weight of the composition of a polyether modified silicone having a C12-22 branched hydrocarbon chain, and may comprise (c2) 10% by mass or less relative to the total weight of the composition of a polyether modified silicone having no alkyl chain, wherein, a ratio of the total blending quantity of the component (c1) and the component (c2) relative to a blending quantity of the component (b) is 2 or more, a ratio of the total blending quantity of the component (c1) and the component (c2) to a blending quantity of the component (a) is 0.

Abstract: Disclosed herein is a hair care product is provided, which comprises an oil-in-water emulsion A and an oil-in-water emulsion C, wherein emulsion A has a pH-value from greater than 7.0 to 12.0 and contains: a1) at least one cationic surfactant A, and a2) at least one amino-functionalized silicone A; and emulsion C has a pH-value from 2.0 to lower than 7.0, and contains: c1) at least one cationic surfactant C, wherein surfactant A and surfactant C may be identical with or different from each other, and c2) at least one silicone C, wherein silicone C and the amino-functionalized silicone A may be identical with or different from each other, wherein emulsion A and emulsion C are separated from each other before use. Also disclosed herein is a process for hair caring by using the hair care product as contemplated herein.

Abstract: A multi-phase oral composition with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier, which is rinseable from a surface and/or has a high water dispersibility. A jammed oil-in-water composition with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier, which is rinseable from a surface and/or has a high water dispersibility. Methods of using disclosed compositions for active agent delivery.

Abstract: The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities.

Abstract: A dentifrice composition containing water, a calcium-containing abrasive, a sodium monofluorophosphate, and an alkaline metal fluoride were the composition has a high fluoride uptake.

Abstract: The present disclosure relates to a perfume composition containing an aldehyde perfume ingredient, more particularly to a perfume composition capable of inhibiting odor and unpleasant smell, which may arise when using a formulation containing an amine. The perfume composition of the present disclosure contains a green aldehyde perfume and, thereby, is capable of inhibiting odor and unpleasant smell which arise from a cationic material including an amine. In addition, by mixing a floral or citrus perfume, luxurious and long-lasting fragrance can be provided.

Abstract: The present disclosure relates to a concentrated rinse-off cleansing composition that includes a high concentration of surfactants and conditioning agent(s). For example, the cleansing compositions may include: (a) surfactants system comprising: (i) one or more anionic surfactants selected from: (i-a) alkyl sulfates; alkyl ether sulfates, salts thereof, or a mixture thereof; and (i-b) optionally, one or more non-sulfate anionic surfactants; (ii) one or more alkyl polyglucosides; and (iii) one or more amphoteric surfactants; (b) one or more conditioning agents; and (c) water. The cleansing compositions are particularly useful for cleansing hair.

Abstract: A method for shaping keratin fibres comprising: providing a crosslinking composition, wherein the crosslinking composition comprises: an active agent, wherein the active agent comprises a functional group selected from the group consisting of: —C(?O)—, —C(?O)—H, and —C(?O)—O—; and wherein the active agent is not an acid; and wherein the active agent has a molecular weight of 500 g/mol or less; a photocatalyst; a cosmetically acceptable carrier; and applying the crosslinking composition to keratin fibres, mechanically shaping the keratin fibres with an appliance or implement, and exposing the composition to electromagnetic radiation having a wavelength of from about 300 nm to about 750 nm. Also a related composition, use, kit and process.

Abstract: The present invention relates to a process for dyeing and/or lightening keratin fibres, in particular human keratin fibres such as the hair, using b) one or more disulfide, thiol or protected-thiol fluorescent direct dyes and a) one or more direct dyes different from b). The present invention also relates to a cosmetic composition comprising the dyes defined above, and also to a multi-compartment device containing said dyes. The present invention also relates to the use of the dyes a) and b) for dyeing light or dark keratin fibres, without using an additional dye different from those defined above, for giving the fibres very chromatic, particularly visible colours.

Abstract: The present invention relates to a skin depigmentation composition comprising (i) at least one thiophosphate derivative and (ii) acceptable carriers for topical, oral and/or parenteral administrations to human. The present invention further relates to the cosmetic and medical treatment uses thereof for reducing skin and/or hair pigmentation.

Abstract: The present disclosure relates to anhydrous cosmetic compositions which contain a combination of a strongly swelling and a low-swelling water-absorbing component, an odor-absorbing component and a deodorant active ingredient. These compositions have an outstanding deodorizing effect and improved sensory features and additionally result in a minimization of sweat spots on textiles. Furthermore, the present disclosure relates to a cosmetic product containing these anhydrous compositions and the use of this composition or product for reduction of the body odor released by perspiration. Finally, the present disclosure relates to the use a strongly swelling water-absorbing component in combination with an odor-absorbing component to improve the sensory characteristics of anhydrous deodorant compositions.

Abstract: Provided is a composition including: an acrylamide compound represented by general formula (1) in 20% by mass or greater but 50% by mass or less; a multifunctional monomer in 40% by mass or greater but 70% by mass or less; and a polymerization initiator, where in general formula (1), R1 represents alkyl group containing 1 through 6 carbon atoms, X represents alkylene group containing 1 through 6 carbon atoms, and Y represents any one selected from the group consisting of general formula (2) below and general formula (3) below, where in general formula (2), R2 represents alkyl group containing 1 through 10 carbon atoms, and * represents binding site with X above, where in general formula (3), R2 represents alkyl group containing 1 through 10 carbon atoms, and * represents binding site with X above.

Abstract: The present invention relates to a composition containing first oleosomes having a first distribution D50(1) and second oleosomes having a second size distribution D50(2).

Abstract: Disclosed is to provide a composition for enhancing skin elasticity or improving skin wrinkles, which comprises a polyol as a dispersion medium, and a ginseng cell lysate dispersed in the polyol as an active ingredient. Specifically, the composition according to the present disclosure contains a polyol and all useful substances in ginseng cells dispersed in a polyol as an active ingredient, thereby exhibiting excellent skin elasticity enhancement or skin winkle improvement effects. In addition, the preparing method according to the present disclosure can effectively disperse useful substances in ginseng cells in the polyol by using a micro fluidizer, and thus can exhibit synergistic effects of useful substances in ginseng cells.

Abstract: A substantially solvent-free oat lipid extract containing neutral and polar lipid fractions, a method of manufacturing a substantially solvent-free oat lipid extract and compositions containing it.

Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.

Abstract: A composition and method for the administration of therapeutic and/or diagnostic agents is provided. Specifically, a hybrid system, composed of polymer that harbors drug-loaded lipid nanoparticles, and use thereof for the administration of active agents e.g., anti-cancer agents, is provided.

Abstract: A film forming composition comprises a film forming component and a solvent, wherein the film forming component comprises 0-50 wt % of a first water soluble polymer, 0.3-40 wt % of a second water soluble polymer, 0-15 wt % of plasticizer and 50-70 wt % of active ingredient. The first and second water soluble polymers have a Tg of ?52° C. to 216° C., and difference of Tg values of the first and second water soluble polymer is 62-268° C. The film formed by the film forming composition capable to load high content of active ingredient and lead to fast absorption of active ingredient is provided.

Abstract: Disclosed herein are glucose-sensitive drug delivery systems including polymeric shell encapsulating an active agent. Upon exposure to a sufficient concentration of glucose, the shell is ruptured, releasing the active agent for absorption.

Abstract: The invention relates to an oral tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet.

Abstract: The invention relates to an oral delivery tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising a) directly compressible (DC) sugar alcohol particles, b) non-directly compressible (non-DC) sugar alcohol particles and c) particles comprising gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing water-insoluble components.

Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.

Abstract: The present invention relates to an edible composition having a lipid continuous phase and self-assembled structures, the composition comprising oil, phospholipids, caffeine and water. Further aspects of the invention are the use of a composition to provide controlled release of caffeine, a composition for use in the treatment or prevention of drowsiness, the non-therapeutic use of a composition to increase mental alertness, and an edible capsule.

Abstract: A membrane including a barrier having layers of alginate with different material molar concentrations relative to another material. The layers have a uniform consistency across a thickness of the layers. The thickness is free of laminae and interfaces and forms a single layer morphology that provides permeability for selected molecules.

Abstract: Provided herein are nanoparticles comprising a polyplex core comprising one or more pH-responsive polymers and one or more anionic immune adjuvants, wherein each pH-responsive polymer comprises ionizable amine groups; and a shell of bacterial cell membrane components at least partially coating the polyplex core, wherein the bacterial cell membrane components comprise TLR 2 and/or TLR 4 agonists. Also provided are methods of stimulating an immune response in a mammal using the nanoparticle.

Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

Abstract: The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Abstract: A transdermal film composition including a film forming polymer comprising poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, oleic acid, polyethylene glycol, and atorvastatin calcium. Methods of making the composition and administering the composition to deliver atorvastatin to a subject are also provided.

Abstract: The present invention relates to a pharmaceutical composition comprising pinocarveol for preventing or treating metabolic diseases, and functional food composition using the pharmaceutical composition for improving or alleviating metabolic diseases. Pinocarveol according to the present invention reduces weight, visceral fat, and cholesterol concentration, improves blood liver function index, reduces blood sugar, and additionally inhibits a metabolic inflammation reaction, and thus can be effectively used ultimately as a medical or functional food composition exhibiting prevention or treatment activities for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and syndromes of fatty liver and insulin-resistance.

Abstract: Nutraceutical compositions and the methods for preventing and/or mitigating veisalgia by the administration thereof. The nutraceutical compositions address the challenged state of the individual and potentiate their ability to be compliant with treatment when the metabolic functions of the liver are overwhelmed as alcohol metabolism depletes hepatic supplies of needed molecules. The methods provide the nutraceutical composition directly to the end organs where alcohol and toxin infused blood is also metabolized and neutralized.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of ?-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.

Abstract: Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.

Abstract: The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

Abstract: It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-ribosyltransferase (mARTD) inhibitors in vitro. In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the benzamide comprising compounds disclosed in the invention, such as 4,4?-oxydibenzamide.

Abstract: The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of cardiovascular diseases.

Abstract: A mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The nanocarrier has a mesophase content in the range of 30 wt % to 70 wt %, a microphase content in the range of 30 wt % to 70 wt %, and a mean pore diameter in the range of 1.5 nm to 5.5 nm. A method of preparing the stable mesosilicalite nanocarrier with hierarchical micro/mesopores to load an antioxidant or drug for targeted drug delivery is also described.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and celecoxib.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.

Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Abstract: The present invention relates to a composition for preventing or treating a muscular disease or improving muscle function. The composition includes suberic acid or a pharmaceutically acceptable salt thereof as an active ingredient.